BRIEF-Emergent Biosolutions initiates Niaid-funded phase 1B clinical study
February 01, 2017 at 07:12 AM EST
* Emergent Biosolutions initiates Niaid-funded phase 1B clinical study to evaluate broad-spectrum antiviral UV-4B for dengue
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.